


# Financial Report



The purpose of Idorsia is to discover, develop, and commercialize innovative medicines to help more patients.

We have more ideas, we see more opportunities, and we want to transform the horizon of therapeutic options.

# Contents

4 **Financial Review**

---

15 **Unaudited Interim  
Consolidated Financial Statements**

---

**Contents**



Financial Review

Unaudited Interim  
Consolidated  
Financial Statements

**3**

# Financial Review

## Contents

### > Financial Review

Unaudited Interim  
Consolidated  
Financial Statements

Idorsia measures and reports its non-GAAP operating performance, which management believes more accurately reflects the underlying business performance. The Group believes that these non-GAAP financial measurements provide useful supplementary information for investors. These non-GAAP measures are reported in addition to, not as a substitute for, US GAAP financial performance.

Rounding differences may occur  
nm = not meaningful

# Idorsia's key numbers

## Profit and loss

	US GAAP		First quarter Non-GAAP	
	2023	2022	2023	2022
(in CHF millions, except EPS)				
<b>Net revenue</b>				
Product sales	18	-	18	-
Contract revenue – royalties	-	-	-	-
Contract revenue – milestones	2	5	2	5
Contract revenue – others	1	0	1	0
<b>Operating expenses</b>				
Cost of sales	(1)	-	(1)	-
Research and development	(93)	(95)	(84)	(89)
Selling, general and administrative	(125)	(103)	(117)	(99)
<b>Net results</b>				
Operating income (loss)	(198)	(193)	(181)	(183)
Net income (loss)	(212)	(198)	(189)	(189)
Basic EPS	(1.19)	(1.12)	(1.06)	(1.07)
Diluted EPS	(1.19)	(1.12)	(1.06)	(1.07)

## Cash flow

	First quarter	
	2023	2022
(in CHF millions)		
<b>Cash flow</b>		
Operating cash flow	(250)	(238)
Cash raise	(0)	-
Capital expenditure	(4)	(13)

## Shares

	Mar 31,	Dec 31,
	2023	2022
(in millions)		
<b>Share count</b>		
Issued common shares	187.9	177.6
Equity derivatives	54.0	54.0
Equity instruments	16.6	14.3
<b>Total potential issued shares</b>	<b>258.5</b>	<b>245.9</b>

## Liquidity and indebtedness

	Mar 31,	Dec 31,
	2023	2022
(in CHF millions)		
<b>Liquidity</b>		
Cash and cash equivalents	212	146
Short-term deposits	-	320
Long-term deposits	-	-
<b>Total liquidity</b>	<b>212</b>	<b>466</b>
<b>Indebtedness</b>		
Convertible loan	335	335
Convertible bonds	795	795
Other financial debt	162	162
<b>Total indebtedness</b>	<b>1,292</b>	<b>1,292</b>

## Contents

### > Financial Review

Unaudited Interim  
Consolidated  
Financial Statements

## Revenue

### Revenue

(in CHF millions)	First quarter	
	2023	2022
<b>Revenue</b>		
Product sales	18	-
Contract revenue - royalties	-	-
Contract revenue - milestones	2	5
Contract revenue - others	1	0
<b>US GAAP revenue</b>	<b>21</b>	<b>5</b>

Product sales comprised of the first sales of the two approved products:

- PIVLAZ™ (clazosentan) - which is available in Japan - achieved CHF 13.5 m net sales
- QUVIVIQ™ (daridorexant) - which is available in the US, Germany and Italy - achieved CHF 4.3 m net sales (net sales do not fully reflect the volumes of the products dispensed in the US due to coupon and co-pay programs)

Contract revenue from milestones mainly consisted of Mochida (daridorexant Japan: CHF 1 m) and Neurocrine (license and research & development collaboration: CHF 1 m).

## Operating expenses

### Operating expenses

(in CHF millions)	First quarter	
	2023	2022
<b>Operating expenses</b>		
Cost of sales	1	-
Research	28	30
Development	56	59
Selling	96	81
General and administrative	21	18
Milestones paid	-	-
<b>Non-GAAP operating expenses</b>	<b>202</b>	<b>188</b>
Depreciation and amortization	5	5
Share-based compensation	12	5
Other	-	-
<b>Other operating expenses</b>	<b>17</b>	<b>10</b>
<b>US GAAP operating expenses</b>	<b>219</b>	<b>198</b>

US GAAP operating expenses of CHF 219 m comprised of Non-GAAP operating expenses (CHF 202 m), depreciation and amortization (CHF 5 m) and share-based compensation (CHF 12 m).

### Cost of sales

(in CHF millions)	First quarter	
	2023	2022
<b>Cost of sales</b>		
Cost of goods sold	(0)	-
Royalty paid	1	-
<b>Non-GAAP cost of sales</b>	<b>1</b>	<b>-</b>
Other	-	-
<b>US GAAP cost of sales</b>	<b>1</b>	<b>-</b>

Cost of sales of CHF 1 m mainly included sales-based royalty expenses. The cost of goods sold do not reflect the actual manufacturing costs, as prior to product approval, the manufacturing and related costs were expensed.

## Contents

### > Financial Review

Unaudited Interim  
Consolidated  
Financial Statements

## Research and development (“R&D”) expenses

(in CHF millions)	First quarter	
	2023	2022
<b>R&amp;D expenses</b>		
Research	28	30
Development	56	59
Milestones paid	-	-
<b>Non-GAAP R&amp;D expenses</b>	<b>84</b>	<b>89</b>
Depreciation and amortization	3	4
Share-based compensation	6	2
Other	-	-
<b>US GAAP R&amp;D expenses</b>	<b>93</b>	<b>95</b>

Non-GAAP research expenses of CHF 28 m, comprised of biology (CHF 6 m), chemistry (CHF 9 m) and preclinical activities (CHF 13 m).

Non-GAAP development expenses of CHF 56 m, comprised of CHF 35 m for clinical activities (including CHF 19 m study costs, mainly driven by late stage studies for selatogrel, daridorexant, cenerimod, clazosentan, lucerastat, apocitentan) and CHF 21 m for chemical and pharmaceutical development activities (including CHF 9 m for drug substance and CHF 7 m for drug product).

## Selling, general and administrative (“SG&A”) expenses

(in CHF millions)	First quarter	
	2023	2022
<b>SG&amp;A expenses</b>		
Selling	96	81
General and administrative	21	18
<b>Non-GAAP SG&amp;A expenses</b>	<b>117</b>	<b>99</b>
Depreciation and amortization	1	2
Share-based compensation	6	2
Other	-	-
<b>US GAAP SG&amp;A expenses</b>	<b>125</b>	<b>103</b>

Non-GAAP SG&A expenses of CHF 117 m, comprised of commercial activities (CHF 96 m), information systems (CHF 11 m) and for other support functions (CHF 10 m).

## Contents

### > Financial Review

Unaudited Interim  
Consolidated  
Financial Statements

## Operating results

### Non-GAAP and US GAAP operating results

(in CHF millions)	First quarter	
	2023	2022
<b>Operating results</b>		
Revenues	21	5
Operating expenses	(202)	(188)
<b>Non-GAAP operating income (loss)</b>	<b>(181)</b>	<b>(183)</b>
<b>Operating results</b>		
Revenues	21	5
Operating expenses	(219)	(198)
<b>US GAAP operating income (loss)</b>	<b>(198)</b>	<b>(193)</b>

US GAAP operating loss of CHF 198 m comprised of Non-GAAP operating loss (CHF 181 m), depreciation and amortization (CHF 5 m) and share-based compensation (CHF 12 m).

## Financial results

### Financial results

(in CHF millions)	First quarter	
	2023	2022
<b>Financial results</b>		
Interest income (expense), net	(5)	(4)
Other financial income (expense), net	(2)	(1)
<b>Non-GAAP financial income (expense)</b>	<b>(7)</b>	<b>(5)</b>
Accretion expense	(0)	(0)
Gain (loss) on securities	(7)	1
<b>US GAAP financial income (expense)</b>	<b>(14)</b>	<b>(4)</b>

US GAAP financial expense of CHF 14 m comprised of Non-GAAP financial expense (CHF 7 m) and losses on marketable securities (CHF 7 m).

Non-GAAP financial expense of CHF 7 m mainly included interest expenses on the convertible bonds (CHF 4 m) and interest expense resulting from the sales and lease back transaction (CHF 2 m).

### Contents

#### > Financial Review

Unaudited Interim  
Consolidated  
Financial Statements



## Income tax

### Income tax

(in CHF millions)	First quarter	
	2023	2022
<b>Income tax</b>		
Income tax benefit (expense)	(2)	(2)
<b>Non-GAAP tax benefit (expense)</b>	<b>(2)</b>	<b>(2)</b>
Other tax benefit (expense)	1	0
<b>US GAAP income tax benefit (expense)</b>	<b>(1)</b>	<b>(1)</b>

US GAAP income tax expense of CHF 1 m mainly included the Non-GAAP tax expense of foreign affiliates (CHF 2 m).

Both US- and Non-GAAP income tax expense included an increase of the valuation allowance of CHF 26 m that related to deferred tax assets arising from operating losses which can be carried forward for 7 years.

## Net results, EPS and shares

### Net results

(in CHF millions)	First quarter	
	2023	2022
<b>Non-GAAP operating income (loss)</b>	<b>(181)</b>	<b>(183)</b>
Financial income (expense)	(7)	(5)
Income tax benefit (expense)	(2)	(2)
<b>Non-GAAP net income (loss)</b>	<b>(189)</b>	<b>(189)</b>
<b>US GAAP operating income (loss)</b>	<b>(198)</b>	<b>(193)</b>
Financial income (expense)	(14)	(4)
Income tax benefit (expense)	(1)	(1)
<b>US GAAP net income (loss)</b>	<b>(212)</b>	<b>(198)</b>

US GAAP net loss of CHF 212 m mainly included the Non-GAAP net loss (CHF 189 m), depreciation and amortization (CHF 4 m), share-based compensation (CHF 12 m) and losses on marketable securities (CHF 7 m).

### Contents

#### > Financial Review

Unaudited Interim  
Consolidated  
Financial Statements

## Shares

(in millions)	Issued	Potentially dilutive equity instruments		Total potential issued shares
		Derivatives	Awards	
<b>Dec 31, 2022</b>	<b>177.6</b>	<b>54.0</b>	<b>14.3</b>	<b>245.9</b>
Issued	10.1	-	2.8	12.9
Vested	0.3	-	(0.3)	-
Exercised	-	-	-	-
Forfeited	-	-	(0.3)	(0.3)
Expired	-	-	-	-
<b>Mar 31, 2023</b>	<b>187.9</b>	<b>54.0</b>	<b>16.6</b>	<b>258.5</b>

Issued shares increased to 187.9 million mainly due to the issuance of new shares which are kept as treasury shares and the vesting of equity awards.

Equity derivatives of 54.0 million related to the Group's outstanding convertible debts of which 29.1 million related to convertible loan from J&J, 19.0 million related to the convertible bonds due in 2028 and 5.9 million related to the convertible bonds due in 2024. Refer to Note 16. Borrowings of the 2022 Consolidated Financial Statements.

Equity awards of 16.6 million comprised of 10.1 million share options with a weighted average strike price of CHF 19.65 granted to eligible employees and 6.4 million unvested share units granted to eligible employees.

## Earnings per share (EPS)

(in CHF millions, unless otherwise indicated)	First quarter	
	2023	2022
<b>Non-GAAP net income (loss)</b>	<b>(189)</b>	<b>(189)</b>
Weighted-average number of basic shares (in millions)	178.0	177.1
<b>Non-GAAP basic EPS (in CHF)</b>	<b>(1.06)</b>	<b>(1.07)</b>
Weighted-average number of dilutive shares (in millions)	178.0	177.1
<b>Non-GAAP diluted EPS (in CHF)</b>	<b>(1.06)</b>	<b>(1.07)</b>
<b>US GAAP net income (loss)</b>	<b>(212)</b>	<b>(198)</b>
Weighted-average number of basic shares (in millions)	178.0	177.1
<b>US GAAP basic EPS (in CHF)</b>	<b>(1.19)</b>	<b>(1.12)</b>
Weighted-average number of dilutive shares (in millions)	178.0	177.1
<b>US GAAP diluted EPS (in CHF)</b>	<b>(1.19)</b>	<b>(1.12)</b>

There is no difference between basic and diluted EPS since no shares were considered dilutive due to the net loss.

## Contents

### > Financial Review

Unaudited Interim  
Consolidated  
Financial Statements

## Cash flow and liquidity

### Operating cash flow

(in CHF millions)	First quarter	
	2023	2022
<b>Operating cash flow</b>		
US GAAP net income (loss)	(212)	(198)
Deferred contract revenue and accrued income	(3)	(5)
Deferred taxes	1	0
Depreciation and amortization	5	5
Accretion of convertible debt	0	0
Share-based compensation	12	5
Other non cash items	7	(1)
<b>Net outflows from operations</b>	<b>(190)</b>	<b>(193)</b>
Net change in receivables	0	3
Net change in inventories	(26)	(9)
Net change in trade and other payables	(2)	(10)
Net change in other operating assets and liabilities	(32)	(28)
<b>Change in working capital</b>	<b>(60)</b>	<b>(45)</b>
<b>Operating cash flow</b>	<b>(250)</b>	<b>(238)</b>

Net outflows from operations of CHF 190 m were mainly driven by the Non-GAAP operating loss (CHF 181 m), interest expenses (CHF 5 m) and a release of deferred contract revenue (CHF 3 m).

The net cash outflows in working capital of CHF 60 m were mainly driven by inventory build up (CHF 26 m), and a increase in prepayments (CHF 32 m).

### Cash flow

(in CHF millions)	First quarter	
	2023	2022
<b>Cash flow</b>		
Operating cash flow	(250)	(238)
Acquisition of tangible, intangible and other assets	(4)	(13)
<b>Free cash flow</b>	<b>(254)</b>	<b>(251)</b>
Cash raise	(0)	-
Issuance of convertible bonds	-	-
Other items	(1)	3
<b>Cash flow<sup>1</sup></b>	<b>(254)</b>	<b>(249)</b>

<sup>1</sup>Cash flow is reconciled with the liquidity movements shown below.

The negative cash flow of CHF 254 m was mainly driven by the operating cash outflow (CHF 250 m) and the acquisition of tangible assets (CHF 4 m).

#### Contents

#### > Financial Review

Unaudited Interim  
Consolidated  
Financial Statements

## Liquidity

(in CHF millions)

	<b>Liquidity</b>
<b>Liquidity Dec 31, 2022</b>	<b>466</b>
Liquidity movements Q1	(254)
<b>Liquidity Mar 31, 2023</b>	<b>212</b>

As of March 31, 2023, liquidity of CHF 212 m consisted of cash only .

Liquidity of CHF 212 m was mainly held in Swiss francs (CHF 138 m), US dollars (equivalent of CHF 48 m) and Japanese Yen (equivalent of CHF 18 m).

## Material uncertainty to continue as a going concern

The unaudited interim financial report has been prepared on the basis that the Group will continue as a going concern. This will require to secure additional funding as the liquidity (CHF 212 m as of March 31, 2023) does not cover the negative cashflow for the next twelve months based on our current business plan.

While the Group is actively seeking to raise additional cash, there can be no assurance the necessary funding will be available.

If the Group is unable to obtain adequate resources to fund the operations, the operations will need to be modified. If such measures are not sufficient, and/or additional funding is not obtained in due course, the Group may be forced to discontinue its operations entirely.

This material uncertainty may cast significant doubts about the going concern of the Group. Refer to Note 1. Description of business and summary of significant accounting policies of the 2022 consolidated financial statements for further details regarding the going concern assessment.

## Contents

### > Financial Review

Unaudited Interim  
Consolidated  
Financial Statements

# Balance sheet

## Balance sheet

(in CHF millions)	Mar 31, 2023	Dec 31, 2022
<b>Assets</b>		
Liquidity <sup>1</sup>	212	466
Tangible assets	242	245
Other assets	244	193
<b>Total assets</b>	<b>698</b>	<b>904</b>
<b>Liabilities and equity</b>		
Financial debt	1,292	1,292
Deferred revenue	3	5
Other liabilities	263	268
<b>Total liabilities</b>	<b>1,559</b>	<b>1,565</b>
<b>Total equity</b>	<b>(860)</b>	<b>(661)</b>
<b>Total liabilities and equity</b>	<b>698</b>	<b>904</b>

<sup>1</sup> Liquidity includes cash, cash equivalents, short- and long-term deposits

Tangible assets of CHF 242 m mainly consisted of real-estate (CHF 106 m), right-of-use assets (CHF 96 m) and other fixed assets (CHF 41 m).

Other assets of CHF 244 m comprised of prepayments (CHF 45 m), receivables (CHF 49 m), inventories (CHF 60 m), marketable securities (CHF 8 m), intangible assets (CHF 15 m), pension asset (CHF 51 m) and other assets (CHF 17 m).

Financial debt of CHF 1,292 m comprised of the convertible loan (CHF 335 m), the convertible bonds (CHF 795 m) and a sale and leaseback transaction (CHF 162 m).

Deferred revenue of CHF 3 m related to the collaborations with Mochida (CHF 2 m) and Neurocrine Biosciences (CHF 1 m).

Other liabilities of CHF 263 m included current and noncurrent liabilities. Current liabilities of CHF 163 m mainly comprised of accrued expenses (CHF 127 m), payables (CHF 27 m) and a short-term lease liability (CHF 9 m). Noncurrent liabilities of CHF 101 m mainly comprised of a long-term lease liability (CHF 86 m) and other noncurrent liabilities (CHF 15 m).

## Contents

### > Financial Review

Unaudited Interim  
Consolidated  
Financial Statements

# Reconciliation of US GAAP to non-GAAP results

## Reconciliation of US GAAP to non-GAAP results for the first quarter 2023

(in CHF millions, unless otherwise indicated)	US GAAP results	Depreciation, amortization, impairment	Share-based compensation	Other items	Non-GAAP results
<b>Net revenue</b>					
Product sales	18	-	-	-	18
Contract revenue – royalties	-	-	-	-	-
Contract revenue – milestones	2	-	-	-	2
Contract revenue – others	1	-	-	-	1
<b>Total net revenue</b>	<b>21</b>	<b>-</b>	<b>-</b>	<b>-</b>	<b>21</b>
<b>Operating expenses</b>					
Cost of sales	(1)	-	-	-	(1)
Research and development	(93)	3	6	-	(84)
Selling, general and administrative	(125)	1	6	-	(117)
Amortization of intangible assets	(0)	0	-	-	-
<b>Total operating expenses</b>	<b>(219)</b>	<b>5</b>	<b>12</b>	<b>-</b>	<b>(202)</b>
<b>Operating results</b>	<b>(198)</b>	<b>5</b>	<b>12</b>	<b>-</b>	<b>(181)</b>
Total financial income (expense)	(14)	-	-	7	(7)
<b>Income before income tax benefit (expense)</b>	<b>(211)</b>	<b>5</b>	<b>12</b>	<b>7</b>	<b>(187)</b>
Income tax benefit (expense)	(1)	(0)	(0)	-	(2)
<b>Net income (loss)</b>	<b>(212)</b>	<b>4</b>	<b>12</b>	<b>7</b>	<b>(189)</b>
<b>Basic net income (loss) per share (CHF)</b>	<b>(1.19)</b>	<b>0.02</b>	<b>0.07</b>	<b>0.04</b>	<b>(1.06)</b>
Weighted-average number of basic shares (in millions)	178.0	-	-	-	178.0
<b>Diluted net income (loss) per share (CHF)</b>	<b>(1.19)</b>	<b>0.02</b>	<b>0.07</b>	<b>0.04</b>	<b>(1.06)</b>
Weighted-average number of dilutive shares (in millions)	178.0	-	-	-	178.0

The non-GAAP metrics are reported in addition to, not as a substitute for, US GAAP financial performance, as management believes that they provide useful supplementary information to investors and more accurately reflect the underlying business performance.

### Contents

#### > Financial Review

Unaudited Interim  
Consolidated  
Financial Statements

# Unaudited Interim Consolidated Financial Statements

## Contents

Financial Review

➤ Unaudited Interim  
Consolidated  
Financial Statements



# Interim Consolidated Income Statement

(in CHF thousands, except per share amounts)	Three months ended March 31,	
	2023 (unaudited)	2022 (unaudited)
<b>Net revenue</b>		
Product sales	17,761	-
Contract revenue	3,264	5,183
<b>Total net revenue</b>	<b>21,025</b>	<b>5,183</b>
<b>Operating (expenses)<sup>1</sup></b>		
Cost of sales	(853)	-
Research and development	(92,840)	(94,879)
Selling, general and administrative	(124,501)	(102,598)
Amortization of intangible assets	(420)	(251)
<b>Total operating (expenses)</b>	<b>(218,615)</b>	<b>(197,728)</b>
<b>Operating income (loss)</b>	<b>(197,590)</b>	<b>(192,545)</b>
Interest income (expense), net	(4,577)	(3,946)
Accretion of convertible debt	(314)	(264)
Other financial income (expense), net	(8,788)	334
<b>Total financial income (expense)</b>	<b>(13,679)</b>	<b>(3,876)</b>
<b>Income (loss) before income tax benefit (expense)</b>	<b>(211,269)</b>	<b>(196,421)</b>
Income tax benefit (expense)	(914)	(1,133)
<b>Net income (loss) attributable to Idorsia's shareholders</b>	<b>(212,183)</b>	<b>(197,555)</b>
<b>Basic net income (loss) per share attributable to Idorsia's shareholders</b>	<b>(1.19)</b>	<b>(1.12)</b>
Weighted-average number of common shares (in thousands)	177,984	177,149
<b>Diluted net income (loss) per share attributable to Idorsia's shareholders</b>	<b>(1.19)</b>	<b>(1.12)</b>
Weighted-average number of common shares (in thousands)	177,984	177,149
<b><sup>1</sup>Includes share-based compensation as follows:</b>		
Research and development	5,635	2,295
Selling, general and administrative	6,412	2,367
<b>Total share-based compensation</b>	<b>12,047</b>	<b>4,662</b>

## Contents

Financial Review

➤ **Unaudited Interim  
Consolidated  
Financial Statements**



# Interim Consolidated Statement of Comprehensive Income

(in CHF thousands)	Three months ended March 31,	
	2023	2022
	(unaudited)	(unaudited)
<b>Net income (loss)</b>	<b>(212,183)</b>	<b>(197,555)</b>
Other comprehensive income (loss), net of tax:		
Foreign currency translation adjustments	961	2,004
Change of unrecognized components of net periodic benefit costs	(587)	(311)
<b>Other comprehensive income (loss), net of tax</b>	<b>375</b>	<b>1,693</b>
<b>Comprehensive income (loss)</b>	<b>(211,809)</b>	<b>(195,862)</b>

## Contents

Financial Review

> **Unaudited Interim  
Consolidated  
Financial Statements**

## Interim Consolidated Balance Sheet (1/2)

	<b>Mar 31,</b>	<b>Dec 31,</b>
(in CHF thousands, except number of shares)	<b>2023</b>	<b>2022</b>
	(unaudited)	(audited)
<b>ASSETS</b>		
<b>Current assets</b>		
Cash and cash equivalents	211,691	145,998
Short-term deposits	-	320,000
Trade and other receivables, net	46,209	45,025
Receivables from related parties	2,501	4,323
Inventories	60,157	35,840
Marketable securities	8,327	10,326
Other current assets	45,944	34,925
<b>Total current assets</b>	<b>374,829</b>	<b>596,438</b>
<b>Noncurrent assets</b>		
Property, plant and equipment, net	146,755	147,097
Right-of-use assets	95,648	98,371
Intangible assets, net	14,663	14,756
Pension asset	50,650	30,985
Other noncurrent assets	15,818	16,533
<b>Total noncurrent assets</b>	<b>323,535</b>	<b>307,742</b>
<b>TOTAL ASSETS</b>	<b>698,363</b>	<b>904,180</b>

### Contents

Financial Review

> **Unaudited Interim  
Consolidated  
Financial Statements**

## Interim Consolidated Balance Sheet (2/2)

	<b>Mar 31,</b>	<b>Dec 31,</b>
(in CHF thousands, except number of shares)	<b>2023</b>	<b>2022</b>
	(unaudited)	(audited)
<b>LIABILITIES</b>		
<b>Current liabilities</b>		
Trade and other payables	27,107	25,435
Deferred revenue	3,043	5,205
Lease liability	9,018	8,921
Sales related liabilities	9,992	6,010
Accrued expenses	116,777	124,794
<b>Total current liabilities</b>	<b>165,937</b>	<b>170,364</b>
<b>Noncurrent liabilities</b>		
Convertible loan	334,575	334,575
Convertible bonds	795,483	795,219
Other financial liabilities	162,052	162,001
Lease liability	85,978	88,639
Deferred tax liability	6,590	6,468
Other noncurrent liabilities	8,003	7,870
<b>Total noncurrent liabilities</b>	<b>1,392,681</b>	<b>1,394,773</b>
<b>Total liabilities</b>	<b>1,558,618</b>	<b>1,565,137</b>
<b>EQUITY</b>		
<b>Idorsia's shareholders' equity</b>		
Common shares (par value CHF 0.05 per share, issued and outstanding 187,914,112 and 177,558,532 as of March 31, 2023 and December 31, 2022 respectively; total number of authorized shares, including issued, authorized and conditional, 301,384,831 as of March 31, 2023 and December 31, 2022 respectively)	9,396	8,878
Additional paid-in capital	2,139,335	2,126,859
Accumulated profit (loss)	(3,057,281)	(2,845,098)
Treasury shares	(483)	-
Accumulated other comprehensive income (loss)	48,778	48,403
<b>Total Idorsia's shareholders' equity</b>	<b>(860,255)</b>	<b>(660,958)</b>
<b>TOTAL LIABILITIES AND EQUITY</b>	<b>698,363</b>	<b>904,180</b>

### Contents

Financial Review

➤ **Unaudited Interim  
Consolidated  
Financial Statements**

# Interim Consolidated Statement of Cash Flows

(in CHF thousands)	Three months ended March 31,	
	2023	2022
	(unaudited)	(unaudited)
<b>Cash flow from operating activities</b>		
Net income (loss)	(212,183)	(197,555)
Adjustments to reconcile net income (loss) to net cash provided from operating activities:		
Depreciation and amortization	4,565	5,192
Share-based compensation	12,047	4,662
Accretion of convertible debt	314	264
Fair value changes on securities	6,861	(987)
Release of deferred revenue and accrued income	(2,571)	(5,121)
Deferred taxes	768	373
Changes in operating assets and liabilities:		
Other receivables	114	2,567
Prepayments	(10,505)	(12,670)
Inventories	(25,665)	(9,458)
Trade and other payables	(1,927)	(9,974)
Accrued expenses	383	(2,566)
Provisions	(20,812)	(15,638)
Changes in other operating cash flow items	(1,435)	2,982
<b>Net cash flow provided by (used in) operating activities</b>	<b>(250,046)</b>	<b>(237,928)</b>
<b>Cash flow from investing activities</b>		
Purchase of marketable securities	-	(19)
Purchase of short-term deposits	-	(190,000)
Proceeds from short-term deposits	320,000	484,367
Purchase of property, plant and equipment	(3,579)	(6,644)
Purchase of intangible assets	(16)	(6,457)
<b>Net cash flow provided by (used in) investing activities</b>	<b>316,405</b>	<b>281,247</b>
<b>Cash flow from financing activities</b>		
Issuance of new shares, net	(83)	-
Proceeds from exercise of share options	-	241
<b>Net cash flow provided by (used in) financing activities</b>	<b>(83)</b>	<b>241</b>
Net effect of exchange rates on cash and cash equivalents	(584)	751
<b>Net change in cash and cash equivalents</b>	<b>65,692</b>	<b>44,311</b>
Cash and cash equivalents at beginning of period	145,998	101,352
<b>Cash and cash equivalents at end of period</b>	<b>211,691</b>	<b>145,663</b>

## Contents

Financial Review

➤ [Unaudited Interim Consolidated Financial Statements](#)

# Interim Consolidated Statement of Changes in Equity

(in CHF thousands, except number of shares)	Idorsia's shareholders						Total equity
	Common shares		Additional paid-in capital	Accum. profit (loss)	Treasury shares	Accum. other comprehensive income (loss)	
	Shares	Amount					
<b>At January 1, 2022</b>	<b>176,966,995</b>	<b>8,848</b>	<b>2,100,237</b>	<b>(1,982,079)</b>	<b>-</b>	<b>(22,802)</b>	<b>104,204</b>
<b>Comprehensive income (loss):</b>							
Net income (loss)				(197,555)			(197,555)
Other comprehensive income (loss)						1,693	1,693
<b>Comprehensive income (loss)</b>							<b>(195,862)</b>
Exercise of share options	13,620	1	241				241
Share-based compensation transactions	519,700	26	5,851				5,877
Other <sup>1</sup>				(35,123)			(35,123)
<b>At March 31, 2022 (unaudited)</b>	<b>177,500,315</b>	<b>8,875</b>	<b>2,106,328</b>	<b>(2,214,756)</b>	<b>-</b>	<b>(21,110)</b>	<b>(120,662)</b>
<b>Comprehensive income (loss):</b>							
Net income (loss)				(630,342)			(630,342)
Other comprehensive income (loss)						69,513	69,513
<b>Comprehensive income (loss)</b>							<b>(560,829)</b>
Exercise of share options	6,700	0	118				119
Share-based compensation transactions	51,517	3	20,412				20,415
<b>At December 31, 2022 (audited)</b>	<b>177,558,532</b>	<b>8,878</b>	<b>2,126,859</b>	<b>(2,845,098)</b>	<b>-</b>	<b>48,403</b>	<b>(660,958)</b>
<b>Comprehensive income (loss):</b>							
Net income (loss)				(212,183)			(212,183)
Other comprehensive income (loss)						375	375
<b>Comprehensive income (loss)</b>							<b>(211,809)</b>
Exercise of share options	-	-	-				-
Share-based compensation transactions	355,580	18	7,636				7,654
Transactions in treasury shares	10,000,000	500	4,841		(483)		4,858
<b>At March 31, 2023 (unaudited)</b>	<b>187,914,112</b>	<b>9,396</b>	<b>2,139,335</b>	<b>(3,057,281)</b>	<b>(483)</b>	<b>48,778</b>	<b>(860,255)</b>


<sup>1</sup> Impact on opening balance caused by the adoption of ASU 2020-06 as of January 1, 2022. Refer to Note 16. Borrowings of the 2022 Consolidated Financial Statements.

## Contents

Financial Review

➤ **Unaudited Interim Consolidated Financial Statements**

# Be prepared for more



**Curious to learn more?  
Reach out to us.**

Investor Relations  
Idorsia Pharmaceuticals Ltd  
Hegenheimermattweg 91  
4123 Allschwil  
Switzerland

Phone +41 58 844 10 10  
[investor.relations@idorsia.com](mailto:investor.relations@idorsia.com)  
© Idorsia Pharmaceuticals Ltd 2023  
[www.idorsia.com](http://www.idorsia.com)

All trademarks are legally protected.  
Concept and design: Markenfels AG

